Robert Hazlett
Stock Analyst at BTIG
(1.31)
# 3,658
Out of 5,154 analysts
23
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $5.70 | +321.05% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $72.45 | -17.18% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.34 | +944.78% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $1.29 | +77,419.38% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $161.46 | -39.30% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $6.15 | +875.61% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $6.78 | +829.89% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $9.46 | +206.55% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $0.95 | +2,749,767.79% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.19 | +404.20% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $16.21 | +11.04% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $5.70
Upside: +321.05%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $72.45
Upside: -17.18%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.34
Upside: +944.78%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $1.29
Upside: +77,419.38%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $161.46
Upside: -39.30%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $6.15
Upside: +875.61%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $6.78
Upside: +829.89%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $9.46
Upside: +206.55%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $0.95
Upside: +2,749,767.79%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.19
Upside: +404.20%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $16.21
Upside: +11.04%